JP6952825B2 - 置換n−アセチル−l−システイン誘導体及び関連化合物 - Google Patents
置換n−アセチル−l−システイン誘導体及び関連化合物 Download PDFInfo
- Publication number
- JP6952825B2 JP6952825B2 JP2020069560A JP2020069560A JP6952825B2 JP 6952825 B2 JP6952825 B2 JP 6952825B2 JP 2020069560 A JP2020069560 A JP 2020069560A JP 2020069560 A JP2020069560 A JP 2020069560A JP 6952825 B2 JP6952825 B2 JP 6952825B2
- Authority
- JP
- Japan
- Prior art keywords
- pro
- pharmaceutical composition
- composition according
- administered
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GQBJNMFTJXPBJT-LBPRGKRZSA-N CC(C)(c1ccccc1)SC[C@@H](C(O)=O)NC(C)=O Chemical compound CC(C)(c1ccccc1)SC[C@@H](C(O)=O)NC(C)=O GQBJNMFTJXPBJT-LBPRGKRZSA-N 0.000 description 1
- WSPBIYTZXPCLCG-ZDUSSCGKSA-N CCOC([C@H](CSC(c1ccc(C)cc1)=O)NC(C)=O)=O Chemical compound CCOC([C@H](CSC(c1ccc(C)cc1)=O)NC(C)=O)=O WSPBIYTZXPCLCG-ZDUSSCGKSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
- C07C329/02—Monothiocarbonic acids; Derivatives thereof
- C07C329/04—Esters of monothiocarbonic acids
- C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
R3は
R3は
一般的方法
使用した溶媒はすべて市販されており、更に精製することなく使用した。典型的には、反応物を窒素の不活性雰囲気下で無水溶媒を用いて流した。化合物はケムドロー7、リアクシス、または市販されているならばカタログ名で指定した。
aq. 水性;
DMSO ジメチルスルホキシド;
EtOAc 酢酸エチル;
HOAc 酢酸;
MeOH メタノール;
NMM 4−メチルモルホリン;
ON 一晩;
r.t. 室温;
TFA トリフルオロ酢酸;及び
THF テトラヒドロフラン。
1H−ベンゾトリアゾール(19.4g,163mmol)をTHF(180mL)中に含む溶液にチオニルクロリド(2.96mL,40.8mmol)を添加した。溶液を氷浴で冷却し、0.5時間後(4R)−2−オキソ−チアゾリジン−4−カルボン酸(OTZ、6.00g,40.8mmol)を添加した。溶液を1時間かけて周囲温度までゆっくり加温した。室温で1.25時間後、生じた固体を真空濾過により除去した。固体及びフラスコを洗浄するためにTHF(60mL)を用いて、濾液を(2R)−2−アセチルアミノ−3−メルカプト−プロピオン酸(NAC,6.00g,36.7mmol)及びNMM(4.04mL,36.7mmol)をTHF(30mL)中に含む氷冷溶液に移した。氷浴を外した。30分後、反応は1HNMRにより完了したと見られた。混合物にTFAを添加し、生じた溶液を2つに分け、酢酸エチルで予め洗浄した2つの330gのシリカゲルイスコカラムに適用した。2つのカラムのバイオタージクロマトグラフィー(EtOAc−20% メタノール(0.5% AcOH))により、EtOAcと摩砕し、真空中で乾燥した後、2.36g(HPLC純度:97.35%)の標記化合物が生じた。速く流れるUV活性画分を濃縮し、EtOAcと摩砕することにより更に化合物を得た。次いで、固体を水中に溶解し、濾過し、凍結乾燥させると、標記化合物が白色凍結乾燥物として生じた。この物質をEtOAc母液からのバッチと合わせ、〜1:1 EtOAc−MeOHを用いて25gのシリカゲルに吸着させた。バイオタージ精製(330gのイスコ,EtOAc−20% メタノール(0.5% AcOH)、カラムをEtOAcで予め湿らす)すると、水中に溶解し、濾過し、凍結乾燥させた後、0.84g(淡黄色凍結乾燥物,HPLC純度:94.70%)及び3.74g(白色凍結乾燥物,HPLC純度:96.88%)が生じた。収量:6.94g(65%)。1H NMR(400MHz,DMSO−d6) δ 13.01(br.s,1H),8.95(d,J=2.0Hz,1H),8.33(d,J=8.2Hz,1H),4.61−4.57(m,1H),4.39−4.33(m,1H),3.81(dd,J=11.7,9.0Hz,1H),3.43(dd,J=11.7,2.3Hz,1H),3.39(dd,J=13.3,4.7Hz,1H),3.08(dd,J=13.7,8.6Hz,1H),1.84(s,3H);13C NMR(100.6MHz,DMSO−d6) 200.9,173.5,171.6,169.4,61.7,51.2,32.7,30.0,22.3ppm;MS(ES) m/z:293(M+H)+;HPLC:96.88%(マックスプロット220〜400nm);元素分析(C9H12N2O5S2):計算値:C,36.98%;H,4.14%;N,9.58% 実測値:C,36.80%;H,4.24%;N,9.63%;[α]D 25 −71.58(c 1.0,水)。
1H−ベンゾトリアゾール(7.68g,64.4mmol)をTHF(60mL)中に含む溶液に2−メトキシ−ベンゾイルクロリド(4.36mL,29.3mmol)を添加した。15分後、生じた溶液は曇り、混合物を1.75時間以上撹拌した。生じた固体を真空濾過により除去し、15mLのTHFで洗浄した。15mLのTHFを含む生じた濾液を(2R)−2−アセチルアミノ−3−メルカプト−プロピオン酸(NAC、3.83g,23.4mmol)及びNMM(2.57mL,23.4mmol)をTHF(30mL)中に含む予冷溶液に添加した。氷浴を外した。一晩室温に置いたが、反応は1H NMRにより完了していなかった。さらにNMM(2.57mL,23.4mmol)を添加し、混合物を55℃に一晩加熱した。混合物にTFA(4mL)を添加し、溶液を真空中で濃縮した。残渣をMeOH及びEtOAc中に溶解し、〜80gのシリカゲルに吸着させた。バイオタージシリカゲルクロマトグラフィー(330gのイスコカラム,120mLの1:2 EtOAc−ヘキサン、次いで120mLの1:1 EtOAc−20% MeOH(1% AcOH)勾配)にかけて精製した後、温MeCN/水 1:1混合物(100mL)中に溶解し,真空中でMeCNを除去し、周囲温度で一晩放置した後、沈殿を吸引濾過し、水で洗浄することにより精製した。標記化合物を白色固体として単離した。収量:2.29g(33%)。Mp 179〜181℃;1H NMR(399.7MHz,DMSO−d6) δ 12.89(br.s,1H),8.31(d,J=8.2Hz,1H),7.65(dd,J=7.8,1.6Hz,1H),7.59−7.54(m,1H),7.18(d,J=8.6Hz,1H),7.06−7.02(m,1H),4.42−4.36(m,1H),3.85(s,3H),3.47(dd,J=13.7,5.1Hz,1H),3.11(dd,J=13.7,9.0Hz,1H),1.82(s,3H);13C NMR(100.5MHz,DMSO−d6) 189.4,171.8,169.3,157.4,134.3,129.0,125.9,120.4,113.8,55.9,51.4,30.3,22.3ppm;MS(ES) m/z:298(M+H)+;HPLC:97.72%(マックスプロット220〜400nm);元素分析(C13H15NO5S):計算値:C,52.51%;H,5.09%;N,4.71%;S,10.78% 実測値:C,52.58%;H,5.07%;N,4.82%;S,10.55%;[α]D 25 −21.49(c 1.014,DMSO)。
1H−ベンゾトリアゾール(9.91g,83.2mmol)をTHF(80mL)中に含む溶液に4−メチル−ベンゾイルクロリド(5.00mL,37.8mmol)を添加した。2時間後、生じた固体を真空濾過により除去し、25mLのTHFで洗浄した。25mLのTHF洗浄液を含む生じた濾液を(2R)−2−アセチルアミノ−3−メルカプト−プロピオン酸(NAC,5.55g,34.0mmol)及びNMM(3.74mL,34.0mmol)をTHF(50mL)中に含む予冷溶液に添加した。氷浴を外した。一晩室温に置いたが、反応は1H NMRにより完了していなかった。混合物を55℃に1時間加熱した。混合物にTFA(3.6mL)及び水(100mL)を添加した。溶液を真空中で濃縮して、THFの殆どを除去した。さらに水(80mL)及びジクロロメタン(180mL)を添加し、層を分離した。水性層をジクロロメタンで抽出した。有機層を合わせ、Na2SO4で乾燥し、酢酸エチル(100mL)を添加し、真空中で濃縮してジクロロメタンを除去した。結晶化を開始するために残存する酢酸エチル溶液を冷凍庫中に短時間置いた後、周囲温度で一晩放置した。得られた固体を真空濾過により集め、乾燥後3.28gが生じた。添加した若干のメタノールを含む濾液を85gのシリカゲルに吸着させた。バイオタージカラムクロマトグラフィー(330gのイスコ,ヘキサン−酢酸エチル 1:1(0.5CV)、次いでEtOAc−20% MeOH(1%AcOH)勾配)にかけると、2.62gの物質が生じた。EtOAc沈殿由来の固体及びカラムからの物質を合わせ、温MeCN/水 1:1混合物中に溶解した。MeCNを真空中で除去し、周囲温度で一晩放置した後に形成された沈殿を吸引濾過により集めた。標記化合物を白色固体として単離した。収量:4.81g(50%)。Mp 182〜184℃;1H NMR(399.7MHz,DMSO−d6) 12.98(br.s,1H),8.38(d,J=7.8Hz,1H),7.82(d,J=8.0Hz,2H),7.37(d,J=8.0Hz,2H),4.47−4.42(m,1H),3.55(dd,J=13.7,5.1Hz,1H),3.23(dd,J=13.7,8.6Hz,1H),2.89(s,3H),1.84(s,3H);13C NMR(100.5MHz,DMSO−d6) 189.9,171.7,169.3,144.6,133.6,129.6,127.0,51.4,29.9,22.3,21.2ppm;MS(ES) m/z:282(M+H)+;HPLC:94.77%(マックスプロット220〜400nm);元素分析(C13H15NO4S):計算値:C,55.50%;H,5.37%;N,4.98%;S,11.40% 実測値:C,55.46%;H,5.33%;N,5.08%;S,11.66%;[α]D 25 −23.74(c 1.0,DMSO)。
(2R)−2−アセチルアミノ−3−メルカプト−プロピオン酸(NAC、4.02g,24.6mmol)を水(30mL)中に含む溶液に炭酸ナトリウム(2.64g,24.9mmol)、次いでTHF(30mL)を添加した。次いで、クロロギ酸ベンジル(7.73mL,54.1mmol)を添加した。1時間後、pHを〜8に調節するためにさらに炭酸ナトリウムを添加した。更に0.5時間後、真空中で部分的に濃縮した。水性層をEtOAc(3×)で抽出した後、水性層を2N HClを用いてpH〜3に酸性化した。エーテルを添加し、層を分離した。水性層をEtOAc(2×)で抽出し、有機層を合わせ、Na2SO4で乾燥し、濾過し、真空中で濃縮した。バイオタージカラムクロマトグラフィー(330gのイスコ,1:1 hex/EtOAc(120mL)、次いでEtOAc−20% MeOH(1% AcOH)勾配,サンプルを若干のヘキサンを含むEtOAc中に充填)により精製して、標記化合物を白色固体として得た。収量:2.18g(30%)。Mp 146〜148℃;1H NMR(399.7MHz,DMSO−d6) δ 12.98(br.s,1H),8.33(d,J=8.2Hz,1H),7.40−7.32(m,5H),5.27−5.20(m,2H),4.44−4.38(m,1H),3.35−3.30(dd,H2Oにより部分的に隠れている,1H),3.05(dd,J=14.0,8.6Hz,1H),1.81(s,3H);13C NMR(100.5MHz,DMSO−d6) 171.6,169.6,169.4,135.2,128.54,128.47,128.38,68.9,51.5,32.1,22.3ppm;MS(ES) m/z:298(M+H)+;HPLC:98.22%(マックスプロット220〜400nm);元素分析(C13H15NO5S):計算値:C,52.51%;H,5.09%;N,4.71%;S,10.78% 実測値:C,ペンディング%;H,ペンディング%;N,ペンディング%;S,ペンディング%;[α]D 25 ペンディング(c,)。
1H−NMRスペクトルはバリアン・マーキュリー300MHz NMRで獲得した。純度(%)は210〜400nmの2996ダイオードアレイ検出器を備えているウォーターズ・アライアンス2695 HPLC(ウォーターズ・シンメトリーC18,4.6×75mm,3.5μm)を用いて測定した。
本発明の化合物による 14 C摂取
これらの実験の目的は、14C−シスチン摂取を調べることであった。
本アッセイも上記した脳星状膠細胞腫由来のヒトグリア細胞(1321N1)の細胞培養系を用いる。初めに、細胞をHBBSSで洗浄し、3H−グルタメートを添加する(パーキンエルマー:1mCi/mLストック溶液を希釈し(30μL+500μL HBBSS)、各ウェルに10μLの希釈した放射標識を添加する)。細胞に標識したグルタメートを充填するために1時間インキュベートした後、細胞を再びHBBSSで洗浄し、薬物を添加する。30、90及び180分目に、各ウェルから50μLの細胞外培地をサンプリングし、ベックマンLS 6500シンチレーションカウンターを用いて測定する。
どのようなプロセスで14C−シスチン摂取の抑制が生ずるかを更に解明するために、細胞内システインレベルを測定する。
プレパルス抑制実験
本実験の目的は、統合失調症の予測動物モデルにおいて試験化合物の有効性を立証することであった。
本実験の目的は、試験化合物がCNSに浸透する能力を立証することであった。
本実験の目的は、C57BL/6マウスの脳における試験化合物の薬物動態特性を立証することであった。
Claims (16)
- 経口投与される、請求項1に記載の医薬組成物。
- 直腸内、非経口的、槽内、膣内、経皮、経粘膜、舌下、肺内、腹腔内、局所または口腔投与される、請求項1に記載の医薬組成物。
- 固体形態で投与される、請求項1又は2に記載の医薬組成物。
- カプセルで投与される、請求項1、2及び4のいずれか一項に記載の医薬組成物。
- 軟質ゼラチンカプセルで投与される、請求項5に記載の医薬組成物。
- 硬質ゼラチンカプセルで投与される、請求項5に記載の医薬組成物。
- 錠剤として投与される、請求項1、2及び4のいずれか一項に記載の医薬組成物。
- 腸溶コーティングされた固体形態で投与される、請求項1、2、4及び8のいずれか一項に記載の医薬組成物。
- 式Iの化合物を遅延的に放出する、請求項1−9のいずれか一項に記載の医薬組成物。
- 腸管において、式Iの化合物を放出する、請求項1−10のいずれか一項に記載の医薬組成物。
- 液体形態で投与される、請求項1−3のいずれか一項に記載の医薬組成物。
- 1日に、約0.0001から約2000mg/kgの式Iの化合物が対象に投与される、請求項1−12のいずれか一項に記載の医薬組成物。
- 1日に、約0.001から約15mg/kgの式Iの化合物が対象に投与される、請求項1−12のいずれか一項に記載の医薬組成物。
- 医薬的に許容される担体を含む、請求項1−14のいずれか一項に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021156357A JP7170811B2 (ja) | 2013-11-08 | 2021-09-27 | 置換n-アセチル-l-システイン誘導体及び関連化合物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361902052P | 2013-11-08 | 2013-11-08 | |
US61/902,052 | 2013-11-08 | ||
US201361902669P | 2013-11-11 | 2013-11-11 | |
US61/902,669 | 2013-11-11 | ||
JP2016528225A JP6691044B2 (ja) | 2013-11-08 | 2014-11-07 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016528225A Division JP6691044B2 (ja) | 2013-11-08 | 2014-11-07 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021156357A Division JP7170811B2 (ja) | 2013-11-08 | 2021-09-27 | 置換n-アセチル-l-システイン誘導体及び関連化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020121993A JP2020121993A (ja) | 2020-08-13 |
JP6952825B2 true JP6952825B2 (ja) | 2021-10-27 |
Family
ID=51952031
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016528225A Active JP6691044B2 (ja) | 2013-11-08 | 2014-11-07 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
JP2017213633A Active JP6559756B2 (ja) | 2013-11-08 | 2017-11-06 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
JP2020069560A Active JP6952825B2 (ja) | 2013-11-08 | 2020-04-08 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
JP2021156357A Active JP7170811B2 (ja) | 2013-11-08 | 2021-09-27 | 置換n-アセチル-l-システイン誘導体及び関連化合物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016528225A Active JP6691044B2 (ja) | 2013-11-08 | 2014-11-07 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
JP2017213633A Active JP6559756B2 (ja) | 2013-11-08 | 2017-11-06 | 置換n−アセチル−l−システイン誘導体及び関連化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021156357A Active JP7170811B2 (ja) | 2013-11-08 | 2021-09-27 | 置換n-アセチル-l-システイン誘導体及び関連化合物 |
Country Status (14)
Country | Link |
---|---|
US (7) | US9630937B2 (ja) |
EP (2) | EP3066089B1 (ja) |
JP (4) | JP6691044B2 (ja) |
AU (3) | AU2014346591B2 (ja) |
CA (1) | CA2929655C (ja) |
DK (1) | DK3066089T3 (ja) |
ES (1) | ES2765236T3 (ja) |
HU (1) | HUE048345T2 (ja) |
LT (1) | LT3066089T (ja) |
PL (1) | PL3066089T3 (ja) |
PT (1) | PT3066089T (ja) |
SI (1) | SI3066089T1 (ja) |
WO (1) | WO2015070034A1 (ja) |
ZA (1) | ZA201705288B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2937334B1 (en) * | 2010-03-10 | 2017-04-19 | Promentis Pharmaceuticals, Inc. | Propionic acids, propionic acid esters, and related compounds |
WO2015070034A1 (en) * | 2013-11-08 | 2015-05-14 | Promentis Pharmaceuticals, Inc. | Substituted n-acetyl-l-cysteine derivatives and related compounds |
WO2016192687A1 (en) * | 2015-06-05 | 2016-12-08 | China Medical University | New use of inhibitor of cystine-glutamate transporter |
WO2018107056A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels |
WO2018107040A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof |
US20190177295A1 (en) * | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Process for the preparation of a 1,3-disubstituted pyrazole compound |
WO2023073046A2 (en) | 2021-10-29 | 2023-05-04 | Vib Vzw | Means and methods for chronic wound healing |
CN116535998B (zh) * | 2023-06-20 | 2024-05-17 | 安徽省阳明达新材料科技有限公司 | 一种热熔复合石材玻璃耐热eva胶片的制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1493697A1 (de) * | 1965-02-25 | 1969-11-20 | Hoechst Ag | Verfahren zur Spaltung von Thiolestern aromatischer Carbonsaeuren |
IT1194117B (it) | 1981-11-20 | 1988-09-14 | Isnardi Pietro & C Spa | Derivati salicilici di n-acetilcisteina |
CN85107378A (zh) | 1984-09-13 | 1987-03-18 | 陶氏化学公司 | 从原煤中回收有用煤的起泡剂组合物和泡沫浮选方法 |
US5637616A (en) | 1993-06-18 | 1997-06-10 | Arcturus Pharmaceutical Corporation | Method for treating diseases mediated by proteases |
WO1995017900A1 (en) | 1993-12-30 | 1995-07-06 | Arcturus Pharmaceutical Corporation | Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways |
AU2825295A (en) | 1994-06-13 | 1996-01-05 | Arcturus Pharmaceutical Corporation | Method for the treatment, prevention or minimization of hair loss |
JP3608021B2 (ja) * | 1996-09-05 | 2005-01-05 | 参天製薬株式会社 | 新規含硫黄アミノ酸誘導体 |
EP0945490B1 (en) | 1998-03-24 | 2002-07-03 | Japan Polychem Corporation | Propylene resin composition and stretched film produced therefrom |
WO2000000469A2 (en) * | 1998-06-29 | 2000-01-06 | Parker Hughes Institute | Alkyl ketones as potent anti-cancer agents |
CN1376143A (zh) * | 1999-07-26 | 2002-10-23 | 东丽株式会社 | 羧酸衍生物及以其作为有效成分的粘连分子抑制剂 |
AU2002333018B2 (en) | 2001-09-27 | 2006-08-31 | The Mental Health Research Institute Of Victoria | Modulation of physiological processes and agents useful for same |
CA2478066C (en) | 2001-12-04 | 2009-09-08 | Ben-Gurion University Of The Negev Research And Development Authority | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
CN1233629C (zh) | 2002-11-22 | 2005-12-28 | 贵州省中国科学院天然产物化学重点实验室 | 具有神经营养作用的硫酯类化合物及其它的合成方法和应用 |
FR2856592B1 (fr) | 2003-06-27 | 2008-04-25 | Oreal | Composition cosmetique a base de percuseur(s) de radical thiyl pour la deformation permanente des fibres keratiniques |
US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
KR20080028357A (ko) | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용n-아세틸시스테인 아미드(nac 아미드) |
US20090258917A1 (en) | 2005-10-12 | 2009-10-15 | Benjamin Pelcman | Benzoxazoles Useful in the Treatment of Inflammation |
WO2008066603A2 (en) * | 2006-10-03 | 2008-06-05 | Galleon Pharmaceuticals, Inc. | S-nitrosothiol compounds and related derivatives |
US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
JP5796881B2 (ja) * | 2008-02-07 | 2015-10-21 | マーケット ユニバーシティー | 統合失調症を治療するため及び薬物渇望を低減するためのシステイン及びシスチンプロドラッグ |
EP2265594A2 (en) | 2008-04-16 | 2010-12-29 | Marquette University | Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings |
WO2009137827A2 (en) | 2008-05-09 | 2009-11-12 | Tiara Pharmaceuticals, Inc. | Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation |
CA2755069A1 (en) | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
JP5937968B2 (ja) | 2010-01-29 | 2016-06-22 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Mcl‐1を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 |
EP2937334B1 (en) | 2010-03-10 | 2017-04-19 | Promentis Pharmaceuticals, Inc. | Propionic acids, propionic acid esters, and related compounds |
KR101401744B1 (ko) | 2010-09-06 | 2014-06-02 | 서울대학교산학협력단 | N-아세틸-l-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물 |
US8624052B2 (en) | 2010-11-12 | 2014-01-07 | Promentis Pharmaceuticals, Inc. | S-t-butyl protected cysteine di-peptide analogs and related compounds |
WO2012065110A2 (en) | 2010-11-12 | 2012-05-18 | Promentis Pharmaceuticals, Inc. | S-protected cysteine analogs and related compounds |
EP2665742B1 (en) | 2011-01-20 | 2016-04-20 | Oneday - Biotech And Pharma Ltd. | Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof |
WO2013016727A1 (en) * | 2011-07-28 | 2013-01-31 | Promentis Pharmaceuticals, Inc. | Cysteine prodrugs |
WO2014209412A1 (en) | 2013-06-29 | 2014-12-31 | Viva Pharmaceutical, Inc. | N-acetyl l-cysteine chelates and methods for making and using the same |
JP2016523975A (ja) | 2013-07-10 | 2016-08-12 | グレン・エー・ゴールドスタイン | 穿通性頭部外傷の処置におけるn−アセチルシステインアミドの使用 |
WO2015057791A2 (en) | 2013-10-15 | 2015-04-23 | Goldstein Glenn A | Use of n-acetylcysteine amide for decreasing intracranial pressure |
WO2015070034A1 (en) * | 2013-11-08 | 2015-05-14 | Promentis Pharmaceuticals, Inc. | Substituted n-acetyl-l-cysteine derivatives and related compounds |
US20150209310A1 (en) | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca for the treatment of chronic or low impact brain trauma |
WO2015112724A1 (en) | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca for the treatment of chronic or acute cognitive dysfunction |
-
2014
- 2014-11-07 WO PCT/US2014/064581 patent/WO2015070034A1/en active Application Filing
- 2014-11-07 US US14/535,855 patent/US9630937B2/en active Active
- 2014-11-07 HU HUE14802771A patent/HUE048345T2/hu unknown
- 2014-11-07 AU AU2014346591A patent/AU2014346591B2/en active Active
- 2014-11-07 ES ES14802771T patent/ES2765236T3/es active Active
- 2014-11-07 US US14/535,953 patent/US9012674B1/en active Active
- 2014-11-07 CA CA2929655A patent/CA2929655C/en active Active
- 2014-11-07 PT PT148027717T patent/PT3066089T/pt unknown
- 2014-11-07 EP EP14802771.7A patent/EP3066089B1/en active Active
- 2014-11-07 EP EP19207221.3A patent/EP3674297A1/en active Pending
- 2014-11-07 LT LTEP14802771.7T patent/LT3066089T/lt unknown
- 2014-11-07 SI SI201431469T patent/SI3066089T1/sl unknown
- 2014-11-07 PL PL14802771T patent/PL3066089T3/pl unknown
- 2014-11-07 DK DK14802771.7T patent/DK3066089T3/da active
- 2014-11-07 JP JP2016528225A patent/JP6691044B2/ja active Active
-
2017
- 2017-03-15 US US15/459,840 patent/US10112897B2/en active Active
- 2017-04-07 US US15/481,728 patent/US10358414B2/en active Active
- 2017-08-04 ZA ZA2017/05288A patent/ZA201705288B/en unknown
- 2017-11-06 JP JP2017213633A patent/JP6559756B2/ja active Active
-
2018
- 2018-12-21 AU AU2018282446A patent/AU2018282446B2/en not_active Ceased
-
2019
- 2019-06-17 US US16/443,793 patent/US10961187B2/en active Active
-
2020
- 2020-04-08 JP JP2020069560A patent/JP6952825B2/ja active Active
- 2020-10-21 AU AU2020257084A patent/AU2020257084A1/en not_active Abandoned
-
2021
- 2021-03-29 US US17/216,285 patent/US20210395194A1/en not_active Abandoned
- 2021-09-27 JP JP2021156357A patent/JP7170811B2/ja active Active
-
2023
- 2023-10-17 US US18/488,215 patent/US20240059649A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6952825B2 (ja) | 置換n−アセチル−l−システイン誘導体及び関連化合物 | |
KR101991327B1 (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
JP2022520518A (ja) | パンテテイン誘導体及びその使用 | |
JP7019585B2 (ja) | 核酸プロドラッグ | |
WO2019193161A1 (en) | Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs | |
US20110257222A1 (en) | Compounds and methods for the treatment of pain and other diseases | |
US20130338199A1 (en) | Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease | |
US8541435B2 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD) | |
CN111253412A (zh) | α-倒捻子素衍生物及其应用 | |
CN116496205A (zh) | 一种卡瑞斯汀的盐及其用途 | |
CN112218878A (zh) | Ntcp抑制剂 | |
US9193681B1 (en) | Propionic acids, propionic acid esters, and related compounds | |
US20230159438A1 (en) | Arylamides and methods of use thereof | |
US20230159439A1 (en) | Arylamides and methods of use thereof | |
CN117321023A (zh) | 作为药物活性化合物的间苯二酚衍生物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20210216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210831 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210928 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6952825 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |